Background： Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this s...Background： Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this study was to analyze the correlation between levels of vascular endothelial growth factor （VEGF） and epidermal growth factor receptor （EGFR） in patients with benign and malignant hydrothorax. Methods： The contents of VEGF in the pleural effusion and serum of the patients with malignant pleural effusion （n = 35） and benign pleural effusion （n = 30） were detected by double antibody sandwich enzyme linked immunosorbent assay. The gene copy number level of EGFR in pleural effusion was detected by fluorescence in situ hybridization （FISH）. The points with the highest sensitivity and specificity were selected as the critical values to calculate the diagnostic value of the VEGF in pleural effusion and serum, and EGFR gene copy number in pleural effusion. Results： The contents of VEGF in pleural effusion and serum of patients with malignant hydrothorax were （384.91 ± 120.18）, and （129.62 ±46.35） ng/L, respectively, which were significantly higher than those of the patients with benign hydrothorax （207.97 ± 64.04）, （63.49 ± 24.58） ng/L （P 〈 0.01 ）. The sensitivity and specificity of detecting VEGF in pleural effusion were 80.0% and 96.7% （the boundary value was 297.06 ng/L）, respectively for diagnosing benign and malignant hydrothorax. The sensitivity and specificity of serum were 74.3% and 96.7%, respectively （the boundary value was 99.21 ng/L） for diagnosing benign and malignant hydrothorax. The diagnostic efficiencies of EGFR and VEGF in hydrothorax were similar. There was a significant correlation between EGFR and VEGF in hydrothorax （P 〈 0.01 ）. Conclusions： VEGF and EGFR play important roles in the formation of pleural effusion. VEGF differed significantly in benign and malignant pleural effusions, which contributed to differential diagno展开更多
目的:探讨重组人表皮生长因子对深Ⅱ度烧伤患者创面愈合效果及相关指标因子的影响。方法:选取笔者医院2015年10月-2018年10月收治的深Ⅱ度烧伤患者120例为研究对象,根据随机数字表法分为对照组和观察组,其中对照组患者给予纳米银敷料治...目的:探讨重组人表皮生长因子对深Ⅱ度烧伤患者创面愈合效果及相关指标因子的影响。方法:选取笔者医院2015年10月-2018年10月收治的深Ⅱ度烧伤患者120例为研究对象,根据随机数字表法分为对照组和观察组,其中对照组患者给予纳米银敷料治疗,观察组在对照组的基础上联合重组人表皮生长因子(Recombinant human epidermal growth factor,rhEGF)治疗。观察两组患者创面愈合效果和创面恢复情况,并比较两组患者血清炎症因子水平、VEGF以及FGF水平。结果:观察组创面愈合总有效率、创面愈合时间、分泌物消失时间以及炎性症状消失时间均优于对照组,差异有统计学意义(P<0.05);治疗后第7天观察组TNF-α、IL-1、IL-6以及VEGF水平均低于对照组、EGF高于对照组,差异均有统计学意义(P<0.05)。结论:rhEGF治疗深Ⅱ度烧伤患者可降低机体炎症反应,并加速创面愈合。展开更多
Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of breast cancer are diagnosed annually and more than 170000 are triplenegative. Characteristic feature of triple negative br...Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of breast cancer are diagnosed annually and more than 170000 are triplenegative. Characteristic feature of triple negative breast cancer(TNBC) is that it lacks expression of oestrogen,progesterone and human epidermal growth factor receptor-2/neu receptors. They comprise 15%-20% of all breast cancers. We did a systematic review of Pub Med and conference databases to identify studies published on biomarkers in TNBC. We included studies with biomarkers including: Epidermal growth factor receptor,vascular endothelial growth factor,c-Myc,C-kit and basal cytokeratins,Poly(ADP-ribose) polymerase-1,p53,tyrosinase kinases,m-TOR,heat and shock proteins and TOP-2A in TNBC. We also looked for studies published on synthetic lethality and inhibition of angiogenesis,growth,and survival pathways. TNBC is a complex disease subtype with many subclasses. Majority TNBC have a basal-like molecular phenotype by gene expression profiling. Their clinical and pathologic features overlap with hereditary BRCA1 related breast cancers. Management of these tumours is a challenge to the clinician because of its aggressive behaviour,poor outcome,and absence of targeted therapies. As the complexity of this disease is being simplified over time new targets are also being discovered for the treatment of this disease. There are many biomarkers in TNBC being used in clinical practice. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies. Many targeted agents are being studied for treatment of TNBC.展开更多
文摘Background： Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this study was to analyze the correlation between levels of vascular endothelial growth factor （VEGF） and epidermal growth factor receptor （EGFR） in patients with benign and malignant hydrothorax. Methods： The contents of VEGF in the pleural effusion and serum of the patients with malignant pleural effusion （n = 35） and benign pleural effusion （n = 30） were detected by double antibody sandwich enzyme linked immunosorbent assay. The gene copy number level of EGFR in pleural effusion was detected by fluorescence in situ hybridization （FISH）. The points with the highest sensitivity and specificity were selected as the critical values to calculate the diagnostic value of the VEGF in pleural effusion and serum, and EGFR gene copy number in pleural effusion. Results： The contents of VEGF in pleural effusion and serum of patients with malignant hydrothorax were （384.91 ± 120.18）, and （129.62 ±46.35） ng/L, respectively, which were significantly higher than those of the patients with benign hydrothorax （207.97 ± 64.04）, （63.49 ± 24.58） ng/L （P 〈 0.01 ）. The sensitivity and specificity of detecting VEGF in pleural effusion were 80.0% and 96.7% （the boundary value was 297.06 ng/L）, respectively for diagnosing benign and malignant hydrothorax. The sensitivity and specificity of serum were 74.3% and 96.7%, respectively （the boundary value was 99.21 ng/L） for diagnosing benign and malignant hydrothorax. The diagnostic efficiencies of EGFR and VEGF in hydrothorax were similar. There was a significant correlation between EGFR and VEGF in hydrothorax （P 〈 0.01 ）. Conclusions： VEGF and EGFR play important roles in the formation of pleural effusion. VEGF differed significantly in benign and malignant pleural effusions, which contributed to differential diagno
文摘目的:探讨重组人表皮生长因子对深Ⅱ度烧伤患者创面愈合效果及相关指标因子的影响。方法:选取笔者医院2015年10月-2018年10月收治的深Ⅱ度烧伤患者120例为研究对象,根据随机数字表法分为对照组和观察组,其中对照组患者给予纳米银敷料治疗,观察组在对照组的基础上联合重组人表皮生长因子(Recombinant human epidermal growth factor,rhEGF)治疗。观察两组患者创面愈合效果和创面恢复情况,并比较两组患者血清炎症因子水平、VEGF以及FGF水平。结果:观察组创面愈合总有效率、创面愈合时间、分泌物消失时间以及炎性症状消失时间均优于对照组,差异有统计学意义(P<0.05);治疗后第7天观察组TNF-α、IL-1、IL-6以及VEGF水平均低于对照组、EGF高于对照组,差异均有统计学意义(P<0.05)。结论:rhEGF治疗深Ⅱ度烧伤患者可降低机体炎症反应,并加速创面愈合。
文摘目的 探讨康复新液联合注射用矛头蝮蛇血凝酶治疗胃溃疡出血的临床疗效。方法 选取2020年12月—2021年12月在中国人民解放军南部战区总医院治疗的86例胃溃疡出血患者,按照治疗方法不同将所有患者分为对照组和治疗组,每组各43例。对照组患者静脉注射注射用矛头蝮蛇血凝酶,将1单位注射用矛头蝮蛇血凝酶溶于10 m L 0.9%氯化钠溶液中,2次/d。治疗组在对照组基础上口服康复新液,10 mL/次,3次/d。两组患者连续治疗3 d。观察两组的临床疗效,比较两组的止血时间、再出血发生率、凝血功能、血清学指标。结果 治疗后,治疗组总有效率为95.35%,显著高于对照组的总有效率81.39%(P<0.05)。治疗后,治疗组止血时间明显短于对照组,再出血发生率低于对照组(P<0.05)。治疗后,两组患者血浆活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)均明显短于治疗前,纤维蛋白原(FIB)水平明显高于治疗前(P<0.05);治疗后,治疗组APTT、PT明显短于对照组,FIB水平明显高于对照组(P<0.05)。治疗后,两组血管内皮生长因子、表皮生长因子受体水平均明显高于治疗前(P<0.05);治疗后,治疗组血管内皮生长因子、表皮生长因子受体水平明显高于对照组(P<0.05)。结论 康复新液联合注射用矛头蝮蛇血凝酶治疗胃溃疡出血疗效确切,可缩短胃溃疡出血患者止血时间,改善凝血功能。
文摘Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of breast cancer are diagnosed annually and more than 170000 are triplenegative. Characteristic feature of triple negative breast cancer(TNBC) is that it lacks expression of oestrogen,progesterone and human epidermal growth factor receptor-2/neu receptors. They comprise 15%-20% of all breast cancers. We did a systematic review of Pub Med and conference databases to identify studies published on biomarkers in TNBC. We included studies with biomarkers including: Epidermal growth factor receptor,vascular endothelial growth factor,c-Myc,C-kit and basal cytokeratins,Poly(ADP-ribose) polymerase-1,p53,tyrosinase kinases,m-TOR,heat and shock proteins and TOP-2A in TNBC. We also looked for studies published on synthetic lethality and inhibition of angiogenesis,growth,and survival pathways. TNBC is a complex disease subtype with many subclasses. Majority TNBC have a basal-like molecular phenotype by gene expression profiling. Their clinical and pathologic features overlap with hereditary BRCA1 related breast cancers. Management of these tumours is a challenge to the clinician because of its aggressive behaviour,poor outcome,and absence of targeted therapies. As the complexity of this disease is being simplified over time new targets are also being discovered for the treatment of this disease. There are many biomarkers in TNBC being used in clinical practice. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies. Many targeted agents are being studied for treatment of TNBC.
